[go: up one dir, main page]

PE20080114A1 - BICYCLE HETEROARYL DERIVATIVES AS MODULATORS OF THE CANABINOID RECEPTOR - Google Patents

BICYCLE HETEROARYL DERIVATIVES AS MODULATORS OF THE CANABINOID RECEPTOR

Info

Publication number
PE20080114A1
PE20080114A1 PE2007000207A PE2007000207A PE20080114A1 PE 20080114 A1 PE20080114 A1 PE 20080114A1 PE 2007000207 A PE2007000207 A PE 2007000207A PE 2007000207 A PE2007000207 A PE 2007000207A PE 20080114 A1 PE20080114 A1 PE 20080114A1
Authority
PE
Peru
Prior art keywords
canabinoid
modulators
chlorophenyl
bis
phenyl
Prior art date
Application number
PE2007000207A
Other languages
Spanish (es)
Inventor
Mrinalkanti Kundu
Neelima Khairatkar-Joshi
Rameswar Madhvrao Pansare
Suhas M Nadkarni
Pollavi V Karnik
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of PE20080114A1 publication Critical patent/PE20080114A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I DONDE X1 ES CR y X2 ES N, o X1 ES N y X2 ES CR; R, R1a, R1b, R2a, R2b, R2c, R2d, R2e, R3a, R3b, R3c, R3d y R3e SON CADA UNO H, CIANO, FORMILO, ACETILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2,3-BIS- (4-CLOROFENIL)-6-FENIL-IMIDAZOL-[1,2-a]- PIRACINA; 2,3-BIS-(4-CLOROFENIL)-6-(3-TRIFLUOROMETIL-FENIL)-IMIDAZO-[1,2-a]-PIRIMIDINA; CLORHIDRATO DE 2,3-BIS-(4-CLOROFENIL)-6-(3-TRIFLUOROMETIL-FENIL)-IMIDAZO-[1,2-a]-PIRIMIDINA; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. LOS COMPUESTOS DESCRITOS SON MODULADORES DEL RECEPTOR CANABINOIDE 1 (CB1) o CANABINOIDE 2 (CB2) Y SON UTILES EN EL TRATAMIENTO TRANSTORNOS NEURODEGENERATIVOS, TRANSTORNOS DE COMER, OBESIDAD, DEJAR DE FUMAR Y DEMAS ENFERMEDADES MEDIADAS POR EL RECEPTOR CANABINOIDEREFERS TO A COMPOUND OF FORMULA I WHERE X1 IS CR and X2 IS N, or X1 IS N and X2 IS CR; R, R1a, R1b, R2a, R2b, R2c, R2d, R2e, R3a, R3b, R3c, R3d and R3e ARE EACH H, CYANE, FORMYL, ACETYL, AMONG OTHERS. PREFERRED COMPOUNDS ARE: 2,3-BIS- (4-CHLOROPHENYL) -6-PHENYL-IMIDAZOLE- [1,2-a] -PYRACINE; 2,3-BIS- (4-CHLOROPHENYL) -6- (3-TRIFLUORomethyl-PHENYL) -IMIDAZO- [1,2-a] -PYRIMIDINE; 2,3-BIS- (4-CHLOROPHENYL) -6- (3-TRIFLUORomethyl-PHENYL) -IMIDAZO- [1,2-a] -PYRIMIDINE HYDROCHLORIDE; AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION AND A PREPARATION PROCEDURE. THE DESCRIBED COMPOUNDS ARE MODULATORS OF THE CANABINOID RECEPTOR 1 (CB1) or CANABINOID 2 (CB2) AND ARE USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS, EATING DISORDERS, OBESITY, CUTTING SMOKING AND DEMANDED CANABINOID DISEASES BY MEDIATED CANABIDES

PE2007000207A 2006-02-27 2007-02-27 BICYCLE HETEROARYL DERIVATIVES AS MODULATORS OF THE CANABINOID RECEPTOR PE20080114A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN275MU2006 2006-02-27
US78105506P 2006-03-10 2006-03-10
IN1146MU2006 2006-07-18
US82147506P 2006-08-04 2006-08-04
IN2088MU2006 2006-12-20

Publications (1)

Publication Number Publication Date
PE20080114A1 true PE20080114A1 (en) 2008-04-16

Family

ID=38437745

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000207A PE20080114A1 (en) 2006-02-27 2007-02-27 BICYCLE HETEROARYL DERIVATIVES AS MODULATORS OF THE CANABINOID RECEPTOR

Country Status (4)

Country Link
AR (1) AR059643A1 (en)
PE (1) PE20080114A1 (en)
TW (1) TW200745126A (en)
WO (1) WO2007096764A2 (en)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2057164A1 (en) 2006-08-07 2009-05-13 Incyte Corporation Triazolotriazines as kinase inhibitors
WO2008027812A2 (en) * 2006-08-28 2008-03-06 Forest Laboratories Holdings Limited Imidazopyridine and imidazopyrimidine derivatives
EP3443958A1 (en) * 2006-11-22 2019-02-20 Incyte Holdings Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
WO2009032754A2 (en) * 2007-08-31 2009-03-12 Kalypsys, Inc. Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
NZ589622A (en) 2008-05-21 2012-10-26 Incyte Corp Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
CN102264721B (en) 2008-11-10 2015-12-09 沃泰克斯药物股份有限公司 Compounds useful as ATR kinase inhibitors
EP2370428B1 (en) 2008-12-11 2016-08-10 Respivert Limited P38 map kinase inhibitors
CN106518856B (en) 2008-12-19 2020-04-28 沃泰克斯药物股份有限公司 Compounds useful as inhibitors of ATR kinase
WO2010079241A1 (en) * 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Use of antagonists and/or inverse agonists of cb1 receptors for the preparation of drugs that increase motor neuron excitability
DK2419429T3 (en) 2009-04-16 2014-06-23 Ct Nac De Investigaciones Oncológicas Cnio IMIDAZOPYRAZINES AS INHIBITORS OF PROTEIN CHINAS
GB0921731D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Theraputic uses
GB0921730D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Method of treatment
ES2608329T3 (en) 2010-02-03 2017-04-07 Incyte Holdings Corporation Imidazo [1,2-b] [1,2,4] triazines as c-Met inhibitors
MX2012013082A (en) 2010-05-12 2013-05-09 Vertex Pharma 2 -aminopyridine derivatives useful as inhibitors of atr kinase.
US9062008B2 (en) 2010-05-12 2015-06-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8969356B2 (en) 2010-05-12 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
SG185524A1 (en) 2010-05-12 2012-12-28 Vertex Pharma Compounds useful as inhibitors of atr kinase
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2013526540A (en) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Compounds useful as ATR kinase inhibitors
US8623869B2 (en) 2010-06-23 2014-01-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
KR101326557B1 (en) * 2011-03-31 2013-11-08 주식회사종근당 Benzamide derivatives as cannabinoid cb1 receptor antagonists
CA2832100A1 (en) 2011-04-05 2012-10-11 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of tra kinase
JP2014520161A (en) 2011-06-22 2014-08-21 バーテックス ファーマシューティカルズ インコーポレイテッド Compounds useful as ATR kinase inhibitors
US9096602B2 (en) 2011-06-22 2015-08-04 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
CN103958507A (en) 2011-09-30 2014-07-30 沃泰克斯药物股份有限公司 Compounds useful as inhibitors of ATR kinase
EP3733185B1 (en) 2011-09-30 2022-12-07 Vertex Pharmaceuticals Incorporated Treating non-small cell lung cancer with atr inhibitors
WO2013049720A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013049719A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CA2850566C (en) 2011-09-30 2022-05-03 Vertex Pharmaceuticals Incorporated Process for making 4-[chloro-n-hydroxycarbonimidoyl]phenyl derivative
WO2013071088A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8846918B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071093A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
WO2013071090A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8841449B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2802586B1 (en) 2012-01-10 2016-05-25 Bayer Intellectual Property GmbH Substituted imidazopyrazines as akt kinase inhibitors
EP2833973B1 (en) 2012-04-05 2017-09-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
US8999632B2 (en) 2012-10-04 2015-04-07 Vertex Pharmaceuticals Incorporated Method for measuring ATR inhibition mediated increases in DNA damage
US8912198B2 (en) 2012-10-16 2014-12-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
SI2925757T1 (en) 2012-11-19 2018-01-31 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
DK3418281T3 (en) 2012-12-07 2020-12-07 Vertex Pharma PYRAZOLO [1,5-A] PYRIMIDINES USE AS ATR-KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES
CN103012284A (en) * 2012-12-26 2013-04-03 无锡捷化医药科技有限公司 Preparation method of 2-amino-5-bromopyrimidine compound
AU2014208964B2 (en) 2013-01-23 2016-09-01 Astrazeneca Ab Chemical compounds
JP2016512815A (en) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Condensed pyrazolopyrimidine derivatives useful as inhibitors of ATR kinase
PT3077397T (en) 2013-12-06 2020-01-22 Vertex Pharma 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
GB201321736D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
KR102575125B1 (en) 2014-06-05 2023-09-07 버텍스 파마슈티칼스 인코포레이티드 Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
DK3157566T3 (en) 2014-06-17 2019-07-22 Vertex Pharma METHOD OF TREATING CANCER USING A COMBINATION CHK1 AND ATR INHIBITORS
MX395066B (en) 2015-09-30 2025-03-24 Vertex Pharma METHOD FOR TREATING CANCER USING A COMBINATION OF DNA-DAMAGING AGENTS AND ATAXIA TELANGIECTASIA AND RAD3-RELATED PROTEIN (ATR) INHIBITORS.
TW201718581A (en) 2015-10-19 2017-06-01 英塞特公司 Heterocyclic compounds as immunomodulators
SG10202004618TA (en) 2015-11-19 2020-06-29 Incyte Corp Heterocyclic compounds as immunomodulators
US20170174671A1 (en) 2015-12-17 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
SI3394033T1 (en) 2015-12-22 2021-03-31 Incyte Corporation Heterocyclic compounds as immunomodulators
AR108396A1 (en) 2016-05-06 2018-08-15 Incyte Corp HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
MA45116A (en) 2016-05-26 2021-06-02 Incyte Corp HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
ES2927984T3 (en) 2016-06-20 2022-11-14 Incyte Corp Heterocyclic compounds as immunomodulators
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
ES2930092T3 (en) 2016-07-14 2022-12-07 Incyte Corp Heterocyclic compounds as immunomodulators
JP7212612B2 (en) 2016-07-28 2023-01-25 プロメガ コーポレイション coelenterazine analog
CN106317059B (en) * 2016-08-19 2018-10-12 成都理工大学 A kind of 2 (CB2) agonist of Cannabined receptor
CN106317043B (en) * 2016-08-19 2018-11-02 成都理工大学 A kind of 2 agonist of Cannabined receptor
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2929193T3 (en) 2016-12-22 2022-11-25 Incyte Corp Tetrahydroimidazo[4,5-c]pyridine derivatives as inducers of PD-L1 internalization
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
EP3558963B1 (en) 2016-12-22 2022-03-23 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
MX391981B (en) 2016-12-22 2025-03-21 Incyte Corp BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS.
SMT202300065T1 (en) 2018-03-30 2023-05-12 Incyte Corp Heterocyclic compounds as immunomodulators
PL3790877T3 (en) 2018-05-11 2023-06-12 Incyte Corporation Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
GB201811695D0 (en) 2018-07-17 2018-08-29 Salvensis Compounds for use in the treatment of fascioliasis
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
WO2021030162A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
IL291471B2 (en) 2019-09-30 2025-04-01 Incyte Corp Pyrido[3,2-d]pyrimidine compounds as immunomodulators
CN114829366A (en) 2019-11-11 2022-07-29 因赛特公司 Salts and crystalline forms of PD-1/PD-L1 inhibitors
US11866434B2 (en) 2020-11-06 2024-01-09 Incyte Corporation Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
TW202233615A (en) 2020-11-06 2022-09-01 美商英塞特公司 Crystalline form of a pd-1/pd-l1 inhibitor
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
AU2023313032A1 (en) * 2022-07-28 2025-01-23 Ac Immune Sa Novel compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3455924A (en) * 1967-02-08 1969-07-15 Upjohn Co Dianisylimidazoles
ES2140354B1 (en) * 1998-08-03 2000-11-01 S A L V A T Lab Sa IMIDAZO (1,2A) AZINAS SUBSTITUTED AS SELECTIVE INHIBITORS OF COX-2.
JP4025468B2 (en) * 1999-07-29 2007-12-19 三井化学株式会社 Organic electroluminescence device
AU2002319627A1 (en) * 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
KR20060034303A (en) * 2003-07-30 2006-04-21 라보라토리오스 에스.에이.엘.브이.에이.티., 에스.에이. Substituted imidazopyrimidines for preventing and treating cancer

Also Published As

Publication number Publication date
WO2007096764A2 (en) 2007-08-30
TW200745126A (en) 2007-12-16
WO2007096764A3 (en) 2008-07-10
AR059643A1 (en) 2008-04-16

Similar Documents

Publication Publication Date Title
PE20080114A1 (en) BICYCLE HETEROARYL DERIVATIVES AS MODULATORS OF THE CANABINOID RECEPTOR
ECSP10010197A (en) PIRIDINE AND PIRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATION DISORDERS
PE20120534A1 (en) PYRIMIDINES FUSED AS INHIBITORS OF Akt
CL2010001363A1 (en) Compounds derived from 1h-pyrrolo [pyridine or pyrimidine], modulators of the grucocorticoid receptors; preparation procedure; intermediary compounds; pharmaceutical composition; and its use in the treatment of diseases such as type II diabetes, obesity and hypertension, among others
IL204693A0 (en) Imidazo[1, 2 - a] pyrimidine derivatives for the treatment of diseases such as diabetes
CL2008000192A1 (en) COMPOUNDS DERIVED FROM PURINA SUBSTITUTED; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS REJECTION TO TRANSPLANTS, LEUKEMIA, DIABETES, AMONG OTHERS.
SV2010003662A (en) DERIVATIVES OF AZETIDINE AND CYCLLOBUTANE AS JAK INHIBITORS REF. X-19081
CL2009000697A1 (en) Compounds derived from substituted 2-heteroaryl-6-phenyl-imidazol [1,2-a] pyridines; not receptor modulators; intermediate compounds; preparation procedure; pharmaceutical composition; and use in the treatment of cancer, inflammation, neurodegenerative and psychiatric diseases, epilepsy, among others.
IL191763A0 (en) Pyrrolo [2,3-b]pyridine derivatives as h3 receptor modulators
CR20110311A (en) ORGANIC COMPOUNDS
CL2011001685A1 (en) Use of compounds derived from imidazo [4,5-d] pyrimidine, imidazo [4,5-d] pyridazine and pyrrolo [3,2-d] pyrimidine oxo substituted, dpp-4 inhibitors, for the treatment of metabolic diseases in Pediatric patients, such as type 2 diabetes.
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
SV2006002110A (en) THERAPEUTIC COMPOUNDS REF. PC32293A
CL2007001022A1 (en) COMPOUNDS DERIVED FROM 1H-INDOL-2-CARBOXAMIDE; PREPARATION PROCEDURE, PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT AND / OR PREVENTION OF DISEASES ASSOCIATED WITH THE MODULATION OF H3 RECEPTORS AS OBESITY, TYPE II DIABETES AND
CL2007001710A1 (en) Substituted amino-pyrazolopyridine derivatives; Preparation method; pharmaceutical composition; and use in the treatment of diseases such as tumors, rheumatoid arthritis, diseases of deregulated vascular growth, among others.
PE20150902A1 (en) 2-PHENYL-5-HETEROCICLIL-TETRAHIDRO-2H-PIRAN-3-AMINE COMPOUNDS FOR USE IN THE TREATMENT OF DIABETES AND ITS ASSOCIATED DISORDERS
PE20090944A1 (en) BICYCLE PYRIMIDINES FUSED AS INHIBITORS OF THE PI3K / AKT VIA
CL2011000116A1 (en) Compounds derived from imidazo [1,2-a] pyridine; preparation procedure; pharmaceutical composition; intermediate compounds; and use in the treatment of cancer.
CL2007001711A1 (en) Compounds derived from substituted pyrazolopyridine; pharmaceutical composition comprising them; method of preparation of the compounds, intermediates; and their use in the treatment of diseases, such as tumors, rheumatoid arthritis, diseases of deregulated vascular growth, among others.
UY29204A1 (en) IMIDAZO COMPOUNDS (1,2-A) PIRIDINE, COMPOSITIONS, USES AND RELATED METHODS
ECSP055964A (en) HETEROCICLIL-3-SULPHONYLINDAZOLS AS LIGANDS OF 5-HYDROXYTHYRIPTAMINE-6
EA200800992A1 (en) 2-AMINO-7,8-DIHYDRO-6N-PYRIDO [4,3-D] PYRIMIDIN-5-ONES, METHOD OF THEIR PREPARATION, METHOD OF THERAPY WITH THEIR HELP, COMPOSITION COMPONENT AND COMPOSITION ON THEIR BASIS, 2,4-DIOCYRODI CODI, I-2,4-DIOCOCHI. FOR THEIR OBTAINING
ATE430744T1 (en) THIAZOLYLPIPERIDINE DERIVATIVES USEFUL AS H3 RECEPTOR MODULATORS
CL2009001019A1 (en) Compounds derived from pyrrolo [1,2-c] imidazol-3-one, imidazo [indole-3-one and imidazo [1,5-a] pyridin-3-one]; preparation procedure; its pharmaceutical composition; Useful in the treatment of diabetes, obesity, eating disorders or dyslepidemia.
UY29245A1 (en) MEDICAL COMBINATIONS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal